Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: jpbrody who wrote (506)	9/8/1999 8:34:00 AM
From: chalu2	Read Replies (1) \| Respond to of 1025

I'm always confused as to what these buyout numbers might mean to the share price. Does a buyout number of $50 produce a $50 share price, raise the current price by $50, or something else?

To: jpbrody who wrote (506)	9/21/1999 2:05:00 PM
From: rkrw	Read Replies (2) \| Respond to of 1025

<<"Miguasky explicity said that IGEN believes that Roche is only paying half as much as they should in royalties. He also said that the IGEN-licensed Roche products are growing into most of Roche's 20% market share of a $7 billion market. (I read that as saying that IGEN is looking to be getting $126 million/year [9% of 20% of $7 billion]">>> I think you're reading this wrong. Igen stated that Roche is paying half what they should be. Igen reported royalties from Roche of $2.9M last quarter, or about $12M annualized. Take Igen for their word and double it and you get $24M, a far cry from $126M a year. You're reading it as Igen has a piece of ALL Roche diagnostic sales. That is improbable. <<On the basis of that I'm revising my estimate of the buyout to be a minimum of $50/share and it could go as high as (this sounds ridiculous) $300/share.>> I agree, it's ridiculous.